Lead author Improvement RR [CI] Outcome Treatment Control Dose (4d) Gautret 66% 0.34 [0.17-0.68] viral+ 6/20 14/16 2.4g Esper 64% 0.36 [0.15-0.87] hosp. 8/412 12/224 2.0 Huang (ES) 59% 0.41 [0.26-0.66] viral time 32/32 37/37 2.0g (c) Chen (RCT) 72% 0.28 [0.10-0.82] viral time 18/18 12/12 1.6g Hong 65% 0.35 [0.13-0.72] viral+ 42/42 48/48 n/a Bernabeu-Wittel 59% 0.41 [0.36-0.95] death 189 (n) 83 (n) 2.0g Ly 56% 0.44 [0.26-0.75] death 18/116 29/110 2.4g Heras 96% 0.04 [0.02-0.09] death 8/70 16/30 n/a Sulaiman 64% 0.36 [0.17-0.80] death 7/1,817 54/3,724 2.0g Szente Fonseca …
Read MoreDay: October 7, 2021
Accinelli – completing the picture
As noted, 30+ other studies strongly indicate the merits of treating Covid-19 early with Hydroxychloroquine. One notable study not on the list provides quantification and important wider context. Accinelli et al, Hydroxychloroquine / azithromycin in COVID-19: The association between time to treatment and case fatality rate https://www.sciencedirect.com/science/article/pii/S1477893921002040 Summary of importance The Accinelli study has relevance as yet another basic hydroxychloroquine Covid-19 early treatment study. So why is it not on the list? It’s because everyone in the study received HCQ. It has much wider relevance because it studied the effect…
Read More